<DOC>
	<DOCNO>NCT02480803</DOCNO>
	<brief_summary>Both Continuous intrajejunal Levodopa Infusion ( CLI ) Deep Brain Stimulation ( DBS ) accept therapy treatment advance Parkinson 's disease ( PD ) . To date , comparative study execute . The INVEST study open label randomise control trial cost-effectiveness primary outcome . Secondary outcome quality life , neurological impairment , among others .</brief_summary>
	<brief_title>INfusion VErsus STimulation Parkinson 's Disease</brief_title>
	<detailed_description>Rationale : Both Continuous intrajejunal Levodopa Infusion ( CLI ) Deep Brain Stimulation ( DBS ) accept therapy treatment advance Parkinson 's disease ( PD ) . As directly comparative study lack , unknown whether one therapy effective . Besides , CLI seem expensive . To determine optimal treatment advance PD , comparative study CLI DBS warrant . Hypothesis : We hypothesize CLI expensive therapy advance PD DBS surplus cost cost-effective regard benefit patient caregiver quality life , PD symptoms adverse event . Objective : To realize cost-effective treatment strategy advance PD . Study design : Prospective , randomize , open label multicentre trial , two additional patient preference treatment arm ( `` patient preference randomize trial '' ) . Study population : Patients PD , despite optimal pharmacological treatment , severe response fluctuation , dyskinesia , painful dystonia , bradykinesia . A total 66 patient randomize , least 120 patient include patient preference arm . Intervention : Patients randomize DBS CLI . For DBS treatment , 2 electrode implanted brain . The electrode connect implanted pulse generator , place subcutaneously subclavian area . For CLI treatment , tube place jejunum via percutaneous endoscopic gastrostomy ( PEG ) . This tube connect external pump delivers levodopa-gel . Main study parameter : There 6 specify assessment visit : baseline , 1 week , 3 , 6 , 9 , 12 month start study treatment . The primary health economic outcome cost per unit PDQ-39 cost per QALY cost-effectiveness cost-utility analysis , respectively . The EQ-5D applied utility measure . Among secondary outcome quality life , functional health , complication adverse effect , use care perception patient neurologist regard treatment .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Carbidopa , levodopa drug combination</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Idiopathic Parkinson 's Disease bradykinesia least two follow sign ; rest tremor , rigidity , asymmetry ; Despite optimal pharmacological treatment , least one follow symptom : severe response fluctuation , dyskinesia , painful dystonia bradykinesia ; A life expectancy least two year . Age 18 year Previous PDneurosurgery ( e.g. , DBS , pallidotomy , thalamotomy ) ; Previous CLI ( PEGtube Nasal Jejuna| tube ) ; Hoehn Yahr stage 5 best moment day ; Other severely disable disease ; Dementia sign severe cognitive impairment Psychosis ; Current depression ; Contraindications DBS surgery , physical disorder making surgery hazardous ; Contraindications PEG surgery interpose organ , ascites oesophagogastric varix , Duodopa ; Pregnancy , breastfeeding , woman child bear age use reliable method contraception ; No inform consent ; Legally incompetent adult ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Parkinson</keyword>
	<keyword>Parkinson 's Disease</keyword>
	<keyword>Deep Brain Stimulation</keyword>
	<keyword>levodopa-carbidopa</keyword>
	<keyword>Duodopa</keyword>
	<keyword>continuous intrajejunal infusion</keyword>
</DOC>